Skip to main content

Advertisement

SpringerLink
Log in

Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations

  • Letter to the Editor
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

No datasets were generated or analysed during the current study.

References

  1. McKay GA, Beaulieu S, Arhin FF et al (2009) Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 63:1191–1199. https://doi.org/10.1093/jac/dkp126

    Article  CAS  PubMed  Google Scholar 

  2. Corey GR, Kabler H, Mehra P et al (2014) Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 370:2180–2190. https://doi.org/10.1056/NEJMoa1310422

    Article  CAS  PubMed  Google Scholar 

  3. Corey GR, Good S, Jiang H et al (2014) Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 60:254–262. https://doi.org/10.1093/cid/ciu778

    Article  CAS  PubMed  Google Scholar 

  4. Lupia T, De Benedetto I, Bosio R et al (2023) Role of oritavancin in the treatment of infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans: narrative review and possible developments. Life 13:959. https://doi.org/10.3390/life13040959

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chastain DB, Davis A (2019) Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review. Int J Antimicrob Agents 53:429–434. https://doi.org/10.1016/j.ijantimicag.2018.11.023

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland

    Marco Bongiovanni, Beatrice Barda, Niccolò Ramponi & Enos Bernasconi

  2. Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

    Paul Thoueille, Thomas Mercier, Catia Marzolini, Eva Choong & Laurent A. Decosterd

  3. Division of Infectious Diseases and Hospital Epidermiology, University Hospital Basel, Basel, Switzerland

    Marco Bongiovanni, Paul Thoueille, Beatrice Barda, Thomas Mercier, Catia Marzolini, Niccolò Ramponi, Eva Choong, Marco Cantù, Laurent A. Decosterd & Enos Bernasconi

  4. Istituto di Medicina di Laboratorio EOLAB Ente Ospedaliero Cantonale, Bellinzona, Switzerland

    Marco Cantù

  5. University of Geneva, Geneva, Switzerland

    Enos Bernasconi

  6. University of Southern Switzerland, Lugano, Switzerland

    Enos Bernasconi

Authors
  1. Marco Bongiovanni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Thoueille
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beatrice Barda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Mercier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Catia Marzolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Niccolò Ramponi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eva Choong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marco Cantù
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Laurent A. Decosterd
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Enos Bernasconi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MB conceived the study and wrote the manuscript; PT, CM, TM, EC, MC and LAD performed the analyses and revised the manuscript; BB wrote the manuscript, NR and EB collected the data and revised the manuscript.

Corresponding author

Correspondence to Marco Bongiovanni.

Ethics declarations

Competing interests

The authors declare no competing interests.

Transparency declaration

LAD have received from Menarini GmbH (that markets Oritavancin) an honorary for Advisory Board Meetings, a Research Grant for the setting-up of TDM of oritavancin and a Service Contract for oritavancin analyses in patients samples.

All other authors: None to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bongiovanni, M., Thoueille, P., Barda, B. et al. Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations. Eur J Clin Microbiol Infect Dis (2024). https://doi.org/10.1007/s10096-024-04844-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10096-024-04844-5

Search

Navigation